Plasmid-encoded fosfomycin resistance

Fosfomycin ((-)-cis-1,2-epoxypropyl phosphonic acid) was discovered in 1968 as a secondary metabolite of several Streptomyces species. It aroused considerable interest, since it was a completely new molecule having antibacterial activity which exhibited relevant properties, such as a broad spectrum,...

Full description

Saved in:
Bibliographic Details
Published in:Antimicrobial agents and chemotherapy 1991-05, Vol.35 (5), p.791-795
Main Authors: EVARISTO SUAREZ, J, CARMEN MENDOZA, M
Format: Article
Language:English
Subjects:
Animals
Bacteria
Bacteria - drug effects
Bacteria - genetics
Bacteriology
Biological and medical sciences
Drug Resistance, Microbial - genetics
Fosfomycin
Fosfomycin - pharmacology
Fundamental and applied biological sciences. Psychology
Genetics
Humans
Microbiology
Plasmids
Research Article
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-a473t-fdae036e285ba1b644b71e6ddcb463789b45a7d80b56f8a00b8098f8c0db78683
cites
container_end_page 795
container_issue 5
container_start_page 791
container_title Antimicrobial agents and chemotherapy
container_volume 35
creator EVARISTO SUAREZ, J
CARMEN MENDOZA, M
description Fosfomycin ((-)-cis-1,2-epoxypropyl phosphonic acid) was discovered in 1968 as a secondary metabolite of several Streptomyces species. It aroused considerable interest, since it was a completely new molecule having antibacterial activity which exhibited relevant properties, such as a broad spectrum, covering many pathogenic and opportunistic gram-positive (Staphylococcus aureus and Streptococcus spp.) and gram-negative (Pseudomonas aeruginosa, Neisseria spp., and members of the family Enterobacteriaceae) bacteria. The use of fosfomycin has selected another type of resistant organisms which actively incorporate the drug and have a fully sensitive enolpyruvyl transferase, indicating that their mechanism of resistance is different from that of the previously described mutants. They are usually multiresistant, can transfer their resistance through conjugation or transformation, and can be made susceptible through the use of curing agents, indicating a plasmid location for the Fo super(r) determinant.
doi_str_mv 10.1128/AAC.35.5.791
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_245108</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>80692335</sourcerecordid><originalsourceid>FETCH-LOGICAL-a473t-fdae036e285ba1b644b71e6ddcb463789b45a7d80b56f8a00b8098f8c0db78683</originalsourceid><addsrcrecordid>eNqFkctLAzEQh4MotVZvXoVeKghunWwemz14KMUXFPSg55DX6pbdTU1aof-9KS0-DuIphPnmx8w3CJ1iGGOci6vJZDombMzGRYn3UB9DKTLOSr6P-gCcZ1QAPURHMc4h_VkJPdTDglHMyj4aPTUqtrXNXGe8dXZY-Vj5dm3qbhhcrONSdcYdo4NKNdGd7N4Berm9eZ7eZ7PHu4fpZJYpWpBlVlnlgHCXC6YV1pxSXWDHrTWaclKIUlOmCitAM14JBaBFGrYSBqwuBBdkgK63uYuVbp01rlsG1chFqFsV1tKrWv6udPWbfPUfMqcMw6b_fNcf_PvKxaVs62hc06jO-VWUAniZE8L-BZMbkhIhgZdb0AQfY3DV1zAY5Ea_TPolYZLJpD_hF1s8Sc3l3K9Cl3z9xZ79XPY7eHubVB_t6ioa1VQhXaKO31jJgRWCkU8dfJmr</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>15935100</pqid></control><display><type>article</type><title>Plasmid-encoded fosfomycin resistance</title><source>Open Access: PubMed Central</source><source>American Society for Microbiology Journals</source><creator>EVARISTO SUAREZ, J ; CARMEN MENDOZA, M</creator><creatorcontrib>EVARISTO SUAREZ, J ; CARMEN MENDOZA, M</creatorcontrib><description>Fosfomycin ((-)-cis-1,2-epoxypropyl phosphonic acid) was discovered in 1968 as a secondary metabolite of several Streptomyces species. It aroused considerable interest, since it was a completely new molecule having antibacterial activity which exhibited relevant properties, such as a broad spectrum, covering many pathogenic and opportunistic gram-positive (Staphylococcus aureus and Streptococcus spp.) and gram-negative (Pseudomonas aeruginosa, Neisseria spp., and members of the family Enterobacteriaceae) bacteria. The use of fosfomycin has selected another type of resistant organisms which actively incorporate the drug and have a fully sensitive enolpyruvyl transferase, indicating that their mechanism of resistance is different from that of the previously described mutants. They are usually multiresistant, can transfer their resistance through conjugation or transformation, and can be made susceptible through the use of curing agents, indicating a plasmid location for the Fo super(r) determinant.</description><identifier>ISSN: 0066-4804</identifier><identifier>EISSN: 1098-6596</identifier><identifier>DOI: 10.1128/AAC.35.5.791</identifier><identifier>PMID: 1854159</identifier><identifier>CODEN: AACHAX</identifier><language>eng</language><publisher>Washington, DC: American Society for Microbiology</publisher><subject>Animals ; Bacteria ; Bacteria - drug effects ; Bacteria - genetics ; Bacteriology ; Biological and medical sciences ; Drug Resistance, Microbial - genetics ; Fosfomycin ; Fosfomycin - pharmacology ; Fundamental and applied biological sciences. Psychology ; Genetics ; Humans ; Microbiology ; Plasmids ; Research Article</subject><ispartof>Antimicrobial agents and chemotherapy, 1991-05, Vol.35 (5), p.791-795</ispartof><rights>1991 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a473t-fdae036e285ba1b644b71e6ddcb463789b45a7d80b56f8a00b8098f8c0db78683</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.asm.org/doi/pdf/10.1128/AAC.35.5.791$$EPDF$$P50$$Gasm2$$H</linktopdf><linktohtml>$$Uhttps://journals.asm.org/doi/full/10.1128/AAC.35.5.791$$EHTML$$P50$$Gasm2$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,3188,27924,27925,52751,52752,52753,53791,53793</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=19605785$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/1854159$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>EVARISTO SUAREZ, J</creatorcontrib><creatorcontrib>CARMEN MENDOZA, M</creatorcontrib><title>Plasmid-encoded fosfomycin resistance</title><title>Antimicrobial agents and chemotherapy</title><addtitle>Antimicrob Agents Chemother</addtitle><description>Fosfomycin ((-)-cis-1,2-epoxypropyl phosphonic acid) was discovered in 1968 as a secondary metabolite of several Streptomyces species. It aroused considerable interest, since it was a completely new molecule having antibacterial activity which exhibited relevant properties, such as a broad spectrum, covering many pathogenic and opportunistic gram-positive (Staphylococcus aureus and Streptococcus spp.) and gram-negative (Pseudomonas aeruginosa, Neisseria spp., and members of the family Enterobacteriaceae) bacteria. The use of fosfomycin has selected another type of resistant organisms which actively incorporate the drug and have a fully sensitive enolpyruvyl transferase, indicating that their mechanism of resistance is different from that of the previously described mutants. They are usually multiresistant, can transfer their resistance through conjugation or transformation, and can be made susceptible through the use of curing agents, indicating a plasmid location for the Fo super(r) determinant.</description><subject>Animals</subject><subject>Bacteria</subject><subject>Bacteria - drug effects</subject><subject>Bacteria - genetics</subject><subject>Bacteriology</subject><subject>Biological and medical sciences</subject><subject>Drug Resistance, Microbial - genetics</subject><subject>Fosfomycin</subject><subject>Fosfomycin - pharmacology</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Genetics</subject><subject>Humans</subject><subject>Microbiology</subject><subject>Plasmids</subject><subject>Research Article</subject><issn>0066-4804</issn><issn>1098-6596</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1991</creationdate><recordtype>article</recordtype><recordid>eNqFkctLAzEQh4MotVZvXoVeKghunWwemz14KMUXFPSg55DX6pbdTU1aof-9KS0-DuIphPnmx8w3CJ1iGGOci6vJZDombMzGRYn3UB9DKTLOSr6P-gCcZ1QAPURHMc4h_VkJPdTDglHMyj4aPTUqtrXNXGe8dXZY-Vj5dm3qbhhcrONSdcYdo4NKNdGd7N4Berm9eZ7eZ7PHu4fpZJYpWpBlVlnlgHCXC6YV1pxSXWDHrTWaclKIUlOmCitAM14JBaBFGrYSBqwuBBdkgK63uYuVbp01rlsG1chFqFsV1tKrWv6udPWbfPUfMqcMw6b_fNcf_PvKxaVs62hc06jO-VWUAniZE8L-BZMbkhIhgZdb0AQfY3DV1zAY5Ea_TPolYZLJpD_hF1s8Sc3l3K9Cl3z9xZ79XPY7eHubVB_t6ioa1VQhXaKO31jJgRWCkU8dfJmr</recordid><startdate>19910501</startdate><enddate>19910501</enddate><creator>EVARISTO SUAREZ, J</creator><creator>CARMEN MENDOZA, M</creator><general>American Society for Microbiology</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7T7</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>P64</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>19910501</creationdate><title>Plasmid-encoded fosfomycin resistance</title><author>EVARISTO SUAREZ, J ; CARMEN MENDOZA, M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a473t-fdae036e285ba1b644b71e6ddcb463789b45a7d80b56f8a00b8098f8c0db78683</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1991</creationdate><topic>Animals</topic><topic>Bacteria</topic><topic>Bacteria - drug effects</topic><topic>Bacteria - genetics</topic><topic>Bacteriology</topic><topic>Biological and medical sciences</topic><topic>Drug Resistance, Microbial - genetics</topic><topic>Fosfomycin</topic><topic>Fosfomycin - pharmacology</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Genetics</topic><topic>Humans</topic><topic>Microbiology</topic><topic>Plasmids</topic><topic>Research Article</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>EVARISTO SUAREZ, J</creatorcontrib><creatorcontrib>CARMEN MENDOZA, M</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Antimicrobial agents and chemotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>EVARISTO SUAREZ, J</au><au>CARMEN MENDOZA, M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Plasmid-encoded fosfomycin resistance</atitle><jtitle>Antimicrobial agents and chemotherapy</jtitle><addtitle>Antimicrob Agents Chemother</addtitle><date>1991-05-01</date><risdate>1991</risdate><volume>35</volume><issue>5</issue><spage>791</spage><epage>795</epage><pages>791-795</pages><issn>0066-4804</issn><eissn>1098-6596</eissn><coden>AACHAX</coden><abstract>Fosfomycin ((-)-cis-1,2-epoxypropyl phosphonic acid) was discovered in 1968 as a secondary metabolite of several Streptomyces species. It aroused considerable interest, since it was a completely new molecule having antibacterial activity which exhibited relevant properties, such as a broad spectrum, covering many pathogenic and opportunistic gram-positive (Staphylococcus aureus and Streptococcus spp.) and gram-negative (Pseudomonas aeruginosa, Neisseria spp., and members of the family Enterobacteriaceae) bacteria. The use of fosfomycin has selected another type of resistant organisms which actively incorporate the drug and have a fully sensitive enolpyruvyl transferase, indicating that their mechanism of resistance is different from that of the previously described mutants. They are usually multiresistant, can transfer their resistance through conjugation or transformation, and can be made susceptible through the use of curing agents, indicating a plasmid location for the Fo super(r) determinant.</abstract><cop>Washington, DC</cop><pub>American Society for Microbiology</pub><pmid>1854159</pmid><doi>10.1128/AAC.35.5.791</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0066-4804
ispartof Antimicrobial agents and chemotherapy, 1991-05, Vol.35 (5), p.791-795
issn 0066-4804
1098-6596
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_245108
source Open Access: PubMed Central; American Society for Microbiology Journals
subjects Animals
Bacteria
Bacteria - drug effects
Bacteria - genetics
Bacteriology
Biological and medical sciences
Drug Resistance, Microbial - genetics
Fosfomycin
Fosfomycin - pharmacology
Fundamental and applied biological sciences. Psychology
Genetics
Humans
Microbiology
Plasmids
Research Article
title Plasmid-encoded fosfomycin resistance
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T13%3A19%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Plasmid-encoded%20fosfomycin%20resistance&rft.jtitle=Antimicrobial%20agents%20and%20chemotherapy&rft.au=EVARISTO%20SUAREZ,%20J&rft.date=1991-05-01&rft.volume=35&rft.issue=5&rft.spage=791&rft.epage=795&rft.pages=791-795&rft.issn=0066-4804&rft.eissn=1098-6596&rft.coden=AACHAX&rft_id=info:doi/10.1128/AAC.35.5.791&rft_dat=%3Cproquest_pubme%3E80692335%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-a473t-fdae036e285ba1b644b71e6ddcb463789b45a7d80b56f8a00b8098f8c0db78683%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=15935100&rft_id=info:pmid/1854159&rfr_iscdi=true